Sector News

Mallinckrodt amps up hospital business with $1.3B Therakos buy

August 11, 2015
Life sciences
Mallinckrodt has made its second buy of the year–and the company believes it’s the perfect match for its first purchase.
 
The Irish drugmaker agreed to fork over about $1.33 billion to investment firm The Gores Group for immunotherapy maker Therakos in a deal that should bolster its hospital offerings. Therakos specializes in extracorporeal photopheresis, a form of therapy approved to treat symptoms associated with a common form of skin cancer.
 
The acquisition fits “hand-in-glove” with Mallinckrodt’s ($MNK) previous deal–a $2.3 billion purchase of Ikaria that brought it access to a respiratory med for babies in neonatal ICUs, execs said on a conference call, as quoted by Reuters. Mallinckrodt can reach out to medical establishments already using that treatment–dubbed INOmax–to help build demand for Therakos’ devices, which they forecast could haul in $500 million or more per year.
 
The pact may come as no surprise to some industry watchers. Mallinckrodt has been on an M&A spree lately, last year shelling out $5.8 billion for Questcor Pharmaceuticals–and its controversial multiple sclerosis med H.P. Acthar Gel–and inking a pact to lay down $1.6 billion for Cadence Pharmaceuticals just two months before that. And Moody’s, for one, last month predicted the Dublin drugmaker would continue to build up its hospital products business, purchasing companies with injectables or other drugs used in a hospital setting.
 
And Mallinckrodt may not stop there. With a limited internal pipeline in its branded business, the company will “likely continue to make acquisitions in order to drive long-term growth,” the investor service wrote in a recent report. But while competitors like Endo ($ENDP) will be able to look to M&A-related synergies for profit-margin gains, Mallinckrodt will likely need to find its own in internal restructuring and shifts in product mix, the Moody’s report predicted.
 
By Carly Helfand
 

comments closed

Related News

March 16, 2025

Merck opens $1B Gardasil manufacturing facility in North Carolina

Life sciences

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated to produce bulk substance for its megablockbuster HPV vaccine Gardasil. Merck built the new plant on the 262-acre campus it has occupied since 2004, where the pharma giant produces a variety of vaccines including shots to prevent chickenpox, measles and rubella.

March 16, 2025

Sun Pharma to acquire Checkpoint Therapeutics

Life sciences

Indian generic drug maker Sun Pharma agreed to acquire US immunotherapy and targeted oncology company Checkpoint Therapeutics for an upfront value of $355 million. The transaction is expected to be completed in the second quarter of 2025 and is subject to customary closing conditions.

March 16, 2025

Mallinckrodt and Endo sign $6.7bn merger deal

Life sciences

Mallinckrodt Pharmaceuticals and Endo have agreed to merge in a $6.7bn deal, combining two pharmaceutical companies that recently emerged from bankruptcy proceedings tied to opioid litigation. According to the 13 March announcement, the merger will create a “larger, more diversified entity”.

How can we help you?

We're easy to reach